Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CAPR Stock Summary
Top 10 Correlated ETFs
CAPR
In the News
How Much Upside is Left in Capricor (CAPR)? Wall Street Analysts Think 229.15%
The mean of analysts' price targets for Capricor (CAPR) points to a 229.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Capricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that the Company is scheduled to present at two upcoming investor conferences.
Can Capricor (CAPR) Climb 261.27% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 261.3% in Capricor (CAPR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, will release its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Thursday, February 29, 2024. Management will then host a webcast and conference call at 4:30 p.m.
Capricor Therapeutics, Inc. (CAPR) Q3 2023 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Aydin Huseynov - Ladenburg Operator Good afternoon, ladies and gentlemen and welcome to the Capricor's Third Quarter 2023 Financial Results and Corporate Update Call.
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 14, 2023. Management will then host a webcast and conference call at 4:30 p.m.
After Plunging -52.01% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)
Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging -50.99% in 4 Weeks, Here's Why the Trend Might Reverse for Capricor (CAPR)
The heavy selling pressure might have exhausted for Capricor (CAPR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Capricor Therapeutics, Inc. (CAPR) Q2 2023 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q2 2023 Earnings Call Transcript August 7, 2023 4:20 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to the Capricor Therapeutics Second Quarter 2023 Financial Results and Corporate Update Call.
Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, will release its financial results for the second quarter ended June 30, 2023, after the market close on Monday, August 7, 2023. Management will then host a webcast and conference call at 4:30 p.m.
CAPR Financial details
CAPR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.27 | 0.02 | 0.01 | 0.1 | 0.94 | |
Net income per share | -1.99 | -0.87 | -0.84 | -1.18 | -0.83 | |
Operating cash flow per share | -1.84 | -0.65 | -0.73 | 0.2 | -0.96 | |
Free cash flow per share | -1.84 | -0.68 | -0.78 | 0.06 | -1.03 | |
Cash per share | 2.66 | 2.1 | 1.51 | 1.69 | 1.47 | |
Book value per share | 1.84 | 1.82 | 1.36 | 0.48 | 0.84 | |
Tangible book value per share | 1.84 | 1.82 | 1.36 | 0.48 | 0.84 | |
Share holders equity per share | 1.84 | 1.82 | 1.36 | 0.48 | 0.84 | |
Interest debt per share | 0.91 | 0.02 | 0.12 | 0.04 | 0.15 | |
Market cap | 4.75M | 53.23M | 67.65M | 94.77M | 130.95M | |
Enterprise value | 4.23M | 20.88M | 35.64M | 87.73M | 121.86M | |
P/E ratio | -0.64 | -3.95 | -3.49 | -3.27 | -5.88 | |
Price to sales ratio | 4.72 | 171.58 | 276.24 | 37.18 | 5.2 | |
POCF ratio | -0.7 | -5.29 | -4.02 | 19.28 | -5.12 | |
PFCF ratio | -0.7 | -5.02 | -3.76 | 60.87 | -4.74 | |
P/B Ratio | 0.69 | 1.89 | 2.16 | 8.04 | 5.79 | |
PTB ratio | 0.69 | 1.89 | 2.16 | 8.04 | 5.79 | |
EV to sales | 4.2 | 67.31 | 145.52 | 34.42 | 4.84 | |
Enterprise value over EBITDA | -0.54 | -1.52 | -1.67 | -2.91 | -5.3 | |
EV to operating cash flow | -0.62 | -2.08 | -2.12 | 17.84 | -4.76 | |
EV to free cash flow | -0.62 | -1.97 | -1.98 | 56.35 | -4.41 | |
Earnings yield | -1.55 | -0.25 | -0.29 | -0.31 | -0.17 | |
Free cash flow yield | -1.44 | -0.2 | -0.27 | 0.02 | -0.21 | |
Debt to equity | 0.49 | 0.01 | 0.09 | 0.22 | 0.18 | |
Debt to assets | 0.3 | 0.01 | 0.07 | 0.05 | 0.07 | |
Net debt to EBITDA | 0.07 | 2.36 | 1.5 | 0.23 | 0.39 | |
Current ratio | 11.01 | 11.33 | 8.82 | 1.82 | 1.63 | |
Interest coverage | 0 | 0 | 0 | 17.49 | 0 | |
Income quality | 0.89 | 0.74 | 0.84 | -0.17 | 1.15 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.58 | 17.87 | 31.08 | 4.09 | 0.49 | |
Research and developement to revenue | 5.12 | 27.26 | 55.42 | 8.56 | 1.42 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.05 | 0.07 | -0.68 | 0.08 | |
Capex to revenue | 0 | -1.77 | -4.88 | -1.32 | -0.08 | |
Capex to depreciation | 0 | -3.81 | -4.87 | -6.3 | -1.92 | |
Stock based compensation to revenue | 0.7 | 6.29 | 12.11 | 1.75 | 0.29 | |
Graham number | 9.08 | 5.96 | 5.07 | 3.57 | 3.98 | |
ROIC | -0.73 | -0.47 | -0.55 | -1.76 | -0.85 | |
Return on tangible assets | -0.66 | -0.39 | -0.47 | -0.58 | -0.38 | |
Graham Net | 1.44 | 1.69 | 1.09 | 0.14 | 0.42 | |
Working capital | 8.99M | 30.71M | 32.3M | 19.3M | 19.59M | |
Tangible asset value | 6.83M | 28.2M | 31.37M | 11.79M | 22.6M | |
Net current asset value | 5.61M | 27.26M | 26.47M | 4.58M | 14.72M | |
Invested capital | 0.49 | 0.01 | 0.09 | 0.22 | 0.18 | |
Average receivables | 146.42K | 71.98K | 223.88K | 469.67K | 5.46M | |
Average payables | 1.08M | 1.81M | 3.22M | 4.28M | 5.54M | |
Average inventory | -186.76K | -357.68K | -28K | 1 | 0.5 | |
Days sales outstanding | 31.95 | 65.88 | 583.87 | 78.41 | 150.36 | |
Days payables outstanding | 63.75 | 117.59 | 5.52K | 2.54K | 2.13K | |
Days of inventory on hand | -46.81 | -2.42 | 0 | 0 | 0 | |
Receivables turnover | 11.42 | 5.54 | 0.63 | 4.65 | 2.43 | |
Payables turnover | 5.73 | 3.1 | 0.07 | 0.14 | 0.17 | |
Inventory turnover | -7.8 | -151.02 | 245.7K | 694.87K | 0 | |
ROE | -1.08 | -0.48 | -0.62 | -2.46 | -0.99 | |
Capex per share | 0 | -0.04 | -0.05 | -0.14 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.04 | 0.12 | 0.15 | 0.24 | 0.39 | |
Net income per share | -0.31 | 16.19 | -0.29 | -0.25 | -0.02 | |
Operating cash flow per share | -0.27 | 0.17 | -0.37 | -0.34 | -0.38 | |
Free cash flow per share | -0.32 | 0.15 | -0.38 | -0.37 | -0.4 | |
Cash per share | 1.65 | 1.79 | 1.49K | 1.1 | 1.29 | |
Book value per share | 0.47 | 0.25 | 0.11 | -0.07 | 0.74 | |
Tangible book value per share | 0.47 | 0.25 | 0.11 | -0.07 | 0.74 | |
Share holders equity per share | 0.47 | 0.25 | 0.11 | -0.07 | 0.74 | |
Interest debt per share | 0.06 | 16.55 | 87.85 | 0.09 | 0.13 | |
Market cap | 97.13M | 106.54M | 121.1M | 88.3M | 149.95M | |
Enterprise value | 90.09M | 98.33M | -7.49B | 81.73M | 140.86M | |
P/E ratio | -3.1 | 0.07 | -4.11 | -3.45 | -49.19 | |
Price to sales ratio | 101.46 | 35.67 | 30.91 | 14.27 | 12.4 | |
POCF ratio | -14.07 | 25.31 | -12.86 | -10.04 | -12.93 | |
PFCF ratio | -11.96 | 28.36 | -12.55 | -9.37 | -12.17 | |
P/B Ratio | 8.24 | 17.17 | 44.34 | -49.39 | 6.63 | |
PTB ratio | 8.24 | 17.17 | 44.34 | -49.39 | 6.63 | |
EV to sales | 94.1 | 32.92 | -1.91K | 13.21 | 11.65 | |
Enterprise value over EBITDA | -10.71 | -11.43 | 921.57 | -11.91 | -186.47 | |
EV to operating cash flow | -13.05 | 23.36 | 795.35 | -9.29 | -12.15 | |
EV to free cash flow | -11.09 | 26.17 | 776.11 | -8.67 | -11.43 | |
Earnings yield | -0.08 | 3.84 | -0.06 | -0.07 | -0.01 | |
Free cash flow yield | -0.08 | 0.04 | -0.08 | -0.11 | -0.08 | |
Debt to equity | 0.22 | 0.39 | 814.89 | -1.35 | 0.18 | |
Debt to assets | 0.05 | 0.04 | 48.37 | 0.06 | 0.07 | |
Net debt to EBITDA | 0.84 | 0.95 | 936.47 | 0.96 | 12.02 | |
Current ratio | 1.82 | 1.25 | 1.11 | 0.9 | 1.63 | |
Interest coverage | 8.16 | -0.02 | 0 | 0 | 0 | |
Income quality | 0.89 | -0.54 | 1.28 | 1.38 | 15.21 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.92 | 1.18 | 0.73 | 0.49 | 0.25 | |
Research and developement to revenue | 6.51 | 2.57 | 2.25 | 1.62 | 0.81 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.18 | -0.11 | 0.02 | 0.07 | 0.06 | |
Capex to revenue | -1.28 | -0.15 | -0.06 | -0.1 | -0.06 | |
Capex to depreciation | -6.38 | -1.97 | -0.92 | -2.29 | -2.37 | |
Stock based compensation to revenue | 1.2 | 0.73 | 0.41 | 0.28 | 0.15 | |
Graham number | 1.81 | 9.46 | 0.84 | 0.62 | 0.64 | |
ROIC | -0.48 | 39.17 | 0 | -2.16 | -0.04 | |
Return on tangible assets | -0.16 | 7.59 | -0.16 | -0.17 | -0.01 | |
Graham Net | 0.14 | -0.08 | 2.25K | -0.39 | 0.36 | |
Working capital | 19.3M | 9.46M | 3.77B | -3.4M | 19.59M | |
Tangible asset value | 11.79M | 6.21M | 2.73M | -1.79M | 22.6M | |
Net current asset value | 4.58M | -1.06M | 38.88B | -9.41M | 14.72M | |
Invested capital | 0.22 | 0.39 | 814.89 | -1.35 | 0.18 | |
Average receivables | 547.58K | 547.58K | 274.06M | 274.06M | 5.46M | |
Average payables | 4.39M | 5.13M | 5.28M | -3.39B | -3.39B | |
Average inventory | 0.5 | 1 | 18.88B | 18.88B | 0 | |
Days sales outstanding | 51.48 | 16.5 | 12.58K | 7.97 | 77.22 | |
Days payables outstanding | 2.35K | 63.74 | 1.86K | -2.21M | 1.83K | |
Days of inventory on hand | 0 | 0 | 13.69M | 0 | 0 | |
Receivables turnover | 1.75 | 5.45 | 0.01 | 11.3 | 1.17 | |
Payables turnover | 0.04 | 1.41 | 0.05 | 0 | 0.05 | |
Inventory turnover | 185.09K | 7.66M | 0 | 0 | 0 | |
ROE | -0.66 | 65.85 | -2.7 | 3.57 | -0.03 | |
Capex per share | -0.05 | -0.02 | -0.01 | -0.02 | -0.02 |
CAPR Frequently Asked Questions
What is Capricor Therapeutics, Inc. stock symbol ?
Capricor Therapeutics, Inc. is a US stock , located in San diego of Ca and trading under the symbol CAPR
What is Capricor Therapeutics, Inc. stock quote today ?
Capricor Therapeutics, Inc. stock price is $6.78 today.
Is Capricor Therapeutics, Inc. stock public?
Yes, Capricor Therapeutics, Inc. is a publicly traded company.